Fusion Antibodies PLC Capital Reinvestment Ratio
Fusion Antibodies PLC capital reinvestment ratio. Fusion Antibodies PLC (FAB) has a Capital Reinvestment Ratio of 0.39x as of March 2022, meaning it reinvests 0% of its operating cash flow (GBX174.00K) in capital expenditures (GBX67.00K). Check FAB cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Fusion Antibodies PLC (2016–2018)
Capital reinvestment ratio of Fusion Antibodies PLC from 2016 to 2018. This chart tracks Fusion Antibodies PLC's Capital Reinvestment Ratio across 2 annual periods. Also explore Fusion Antibodies PLC (FAB) equity growth momentum to track the company's year-over-year net asset growth rate.
Fusion Antibodies PLC Capital Reinvestment Ratio by Year (2016–2018)
Fusion Antibodies PLC capital reinvestment ratio by year from 2016 to 2018. For the full cash flow conversion analysis, see FAB cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 5.76x | GBX77.19K | GBX444.60K | ▲ +5481.8% |
| 2016 | 0.10x | GBX346.57K | GBX35.76K | — |